NASDAQ:SWAV

ShockWave Medical Competitors

$137.01
-0.98 (-0.71 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$136.52
Now: $137.01
$139.80
50-Day Range
$92.73
MA: $117.36
$137.99
52-Week Range
$34.41
Now: $137.01
$143.79
Volume368,682 shs
Average Volume461,459 shs
Market Capitalization$4.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26

Competitors

ShockWave Medical (NASDAQ:SWAV) Vs. PODD, ABMD, NVCR, PEN, HRC, and GMED

Should you be buying SWAV stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to ShockWave Medical, including Insulet (PODD), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), and Globus Medical (GMED).

Insulet (NASDAQ:PODD) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Insulet and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet3.33%8.94%2.07%
ShockWave Medical-108.73%-30.28%-25.31%

Analyst Recommendations

This is a breakdown of recent recommendations for Insulet and ShockWave Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet19702.35
ShockWave Medical04202.33

Insulet currently has a consensus target price of $254.2353, indicating a potential downside of 11.46%. ShockWave Medical has a consensus target price of $112.50, indicating a potential downside of 17.89%. Given Insulet's stronger consensus rating and higher possible upside, equities analysts plainly believe Insulet is more favorable than ShockWave Medical.

Institutional and Insider Ownership

88.8% of ShockWave Medical shares are held by institutional investors. 1.1% of Insulet shares are held by company insiders. Comparatively, 15.3% of ShockWave Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Insulet and ShockWave Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million25.70$11.60 million$0.191,511.21
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02

Insulet has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Insulet has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Summary

Insulet beats ShockWave Medical on 10 of the 14 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Abiomed and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
ShockWave Medical-108.73%-30.28%-25.31%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Abiomed and ShockWave Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12202.20
ShockWave Medical04202.33

Abiomed presently has a consensus target price of $348.3333, indicating a potential upside of 4.35%. ShockWave Medical has a consensus target price of $112.50, indicating a potential downside of 17.89%. Given Abiomed's higher possible upside, equities research analysts clearly believe Abiomed is more favorable than ShockWave Medical.

Institutional & Insider Ownership

94.0% of Abiomed shares are held by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are held by institutional investors. 3.4% of Abiomed shares are held by company insiders. Comparatively, 15.3% of ShockWave Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Abiomed and ShockWave Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million17.96$203.01 million$4.7470.42
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02

Abiomed has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Abiomed has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Summary

Abiomed beats ShockWave Medical on 10 of the 13 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares NovoCure and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovoCure4.26%7.40%3.94%
ShockWave Medical-108.73%-30.28%-25.31%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NovoCure and ShockWave Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NovoCure14402.33
ShockWave Medical04202.33

NovoCure presently has a consensus target price of $139.2857, indicating a potential upside of 5.45%. ShockWave Medical has a consensus target price of $112.50, indicating a potential downside of 17.89%. Given NovoCure's higher possible upside, equities research analysts clearly believe NovoCure is more favorable than ShockWave Medical.

Institutional & Insider Ownership

71.1% of NovoCure shares are held by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are held by institutional investors. 5.1% of NovoCure shares are held by company insiders. Comparatively, 15.3% of ShockWave Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NovoCure and ShockWave Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$351.32 million38.51$-7,230,000.00($0.07)-1,887.00
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02

NovoCure has higher revenue and earnings than ShockWave Medical. NovoCure is trading at a lower price-to-earnings ratio than ShockWave Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NovoCure has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Summary

NovoCure beats ShockWave Medical on 10 of the 13 factors compared between the two stocks.

Penumbra (NYSE:PEN) and ShockWave Medical (NASDAQ:SWAV) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Penumbra and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra-1.79%-0.12%-0.09%
ShockWave Medical-108.73%-30.28%-25.31%

Valuation and Earnings

This table compares Penumbra and ShockWave Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million18.11$48.46 million$0.98277.58
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02

Penumbra has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Penumbra has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Penumbra and ShockWave Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra02402.67
ShockWave Medical04202.33

Penumbra presently has a consensus target price of $279.00, indicating a potential upside of 2.56%. ShockWave Medical has a consensus target price of $112.50, indicating a potential downside of 17.89%. Given Penumbra's stronger consensus rating and higher possible upside, equities research analysts clearly believe Penumbra is more favorable than ShockWave Medical.

Institutional & Insider Ownership

88.2% of Penumbra shares are held by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are held by institutional investors. 8.9% of Penumbra shares are held by company insiders. Comparatively, 15.3% of ShockWave Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Penumbra beats ShockWave Medical on 9 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and ShockWave Medical (NASDAQ:SWAV) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Hill-Rom and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.74%22.71%8.01%
ShockWave Medical-108.73%-30.28%-25.31%

Earnings & Valuation

This table compares Hill-Rom and ShockWave Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.88 billion2.60$223 million$5.5320.42
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02

Hill-Rom has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Hill-Rom has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Hill-Rom and ShockWave Medical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
ShockWave Medical04202.33

Hill-Rom presently has a consensus target price of $121.00, indicating a potential upside of 7.14%. ShockWave Medical has a consensus target price of $112.50, indicating a potential downside of 17.89%. Given Hill-Rom's stronger consensus rating and higher possible upside, analysts plainly believe Hill-Rom is more favorable than ShockWave Medical.

Institutional and Insider Ownership

83.8% of Hill-Rom shares are owned by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by company insiders. Comparatively, 15.3% of ShockWave Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Hill-Rom beats ShockWave Medical on 10 of the 14 factors compared between the two stocks.

ShockWave Medical (NASDAQ:SWAV) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares ShockWave Medical and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ShockWave Medical-108.73%-30.28%-25.31%
Globus Medical12.36%9.85%9.04%

Insider & Institutional Ownership

88.8% of ShockWave Medical shares are owned by institutional investors. Comparatively, 64.4% of Globus Medical shares are owned by institutional investors. 15.3% of ShockWave Medical shares are owned by insiders. Comparatively, 25.6% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ShockWave Medical and Globus Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ShockWave Medical$42.93 million111.20$-51,110,000.00($2.14)-64.02
Globus Medical$785.37 million8.51$155.21 million$1.6839.88

Globus Medical has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for ShockWave Medical and Globus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ShockWave Medical04202.33
Globus Medical041002.71

ShockWave Medical currently has a consensus price target of $112.50, indicating a potential downside of 17.89%. Globus Medical has a consensus price target of $66.40, indicating a potential downside of 0.90%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than ShockWave Medical.

Volatility and Risk

ShockWave Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Summary

Globus Medical beats ShockWave Medical on 11 of the 14 factors compared between the two stocks.


ShockWave Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Insulet logo
PODD
Insulet
1.4$287.13-0.9%$18.97 billion$738.20 million652.58
Abiomed logo
ABMD
Abiomed
1.4$333.81-1.2%$15.10 billion$840.88 million73.36News Coverage
NovoCure logo
NVCR
NovoCure
1.5$132.09-0.3%$13.53 billion$351.32 million695.25Analyst Upgrade
Insider Selling
Penumbra logo
PEN
Penumbra
1.5$272.03-0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94-1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00-1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06-2.8%$5.95 billion$988.48 million56.55Gap Up
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$218.45-3.3%$5.93 billion$82.05 million-94.16Gap Up
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12-0.9%$5.92 billion$1.52 billion104.66
Inari Medical logo
NARI
Inari Medical
1.1$113.64-0.2%$5.54 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99-0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08-0.9%$5.09 billion$390.26 million-54.07
ICU Medical logo
ICUI
ICU Medical
1.5$204.19-0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76-1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13-3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76-0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71-1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50-1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90-1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13-0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72-0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14-0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60-1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95-2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48-4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.